Floatz logo

RDX-013 COMPONENT TENAPANOR

Constipation

Massachusetts General HospitalSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Constipation cohort.

Asset / SponsorPhaseRating
N-Methylnaltrexone Bromide
Bausch Health Americas, Inc.
Phase 3BB
Moa-728
Bausch Health Americas, Inc.
Phase 2BB
Lubiprostone
University of Rochester
Phase 4BB
Oxycodone
Mundipharma Research GmbH & Co KG
Phase 3BB
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE
Mundipharma Research GmbH & Co KG
Phase 3BB

View all 28 →

Same molecule, other indications

RDX-013 COMPONENT TENAPANOR is also rated in:

cystic fibrosisDormant
CCC
Indicative ·
54 / 100
View asset →
synucleinopathyDormant
CCC
Indicative ·
53 / 100
View asset →
Parkinson diseaseDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →